Literature DB >> 30888496

Increased TSLP, IL-33, IL-25, IL-19, IL 21 and amphiregulin (AREG) levels in chronic rhinosinusitis with nasal polyp.

Murat Dogan1, Mustafa Sahin2, Cigdem Yenisey3.   

Abstract

OBJECTIVE: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease. The surrogate indicating biomarkers in patients with CRSwNP need further evaluation. The aim of this study was to investigate the association of thymic stromal lymphopoietin (TSLP) and amphiregulin (AREG) cytokines in patients with CRSwNP.
METHODS: Sinonasal tissue samples were collected from 33 patients with CRSwNP and 29 controls. Levels of AREG, IL-19, IL-21, IL-25, IL-33 and TSLP in nasal polyp and control sinonasal tissues were determined following the enzyme-linked immunosorbent assay method.
RESULTS: We found that AREG, IL-19, IL-21, IL-25, IL-33 and TSLP levels were significantly higher in the CRSwNP group compared to the control group (p < 0.000; p < 0.000; p < 0.000; p < 0.000; p < 0.003; p < 0.021, respectively).
CONCLUSIONS: Our findings indicated that AREG, IL-19, IL-21, IL-25, IL-33 and TSLP were significantly increased in tissue samples of CRSwNP patients and may be considered as molecular indicators and targets for therapeutic developments for patients with CRSwNP.

Entities:  

Keywords:  Amphiregulin; Chronic rhinosinusitis; Cytokine; Nasal polyp

Mesh:

Substances:

Year:  2019        PMID: 30888496     DOI: 10.1007/s00405-019-05379-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  31 in total

1.  IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo.

Authors:  M M Fort; J Cheung; D Yen; J Li; S M Zurawski; S Lo; S Menon; T Clifford; B Hunte; R Lesley; T Muchamuel; S D Hurst; G Zurawski; M W Leach; D M Gorman; D M Rennick
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

2.  Increased IL-21 expression in chronic rhinosinusitis with nasalpolyps.

Authors:  L Xiao; Y Wei; Y-N Zhang; X Luo; B-Y Yang; S-F Yu; X-M Wu; C-Y Wu; H-B Li
Journal:  Clin Exp Allergy       Date:  2015-02       Impact factor: 5.018

3.  The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps.

Authors:  Atakan Ozturan; Hulya Eyigor; Mete Eyigor; Ustun Osma; Mustafa Deniz Yilmaz; Omer Tarik Selcuk; Levent Renda; Meral Gultekin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-13       Impact factor: 2.503

Review 4.  Targeting IL-25 as a novel therapy in chronic rhinosinusitis with nasal polyps.

Authors:  Mingyu Lee; Dae Woo Kim; Hyun-Woo Shin
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-02

5.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinology       Date:  2012-03       Impact factor: 3.681

6.  FcepsilonRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells.

Authors:  Shigeru Okumura; Hironori Sagara; Takeshi Fukuda; Hirohisa Saito; Yoshimichi Okayama
Journal:  J Allergy Clin Immunol       Date:  2005-02       Impact factor: 10.793

Review 7.  Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis.

Authors:  Robert P Schleimer
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

8.  Increased expression of IL-19 in the epithelium of patients with chronic rhinosinusitis and nasal polyps.

Authors:  E Pace; V Scafidi; D Di Bona; L Siena; G Chiappara; M Ferraro; S La Grutta; S Gallina; R Speciale; A Ballacchino; C Bachert; J Bousquet; M Gjomarkaj
Journal:  Allergy       Date:  2012-05-14       Impact factor: 13.146

9.  Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.

Authors:  Claus Bachert; Ana R Sousa; Valerie J Lund; Glenis K Scadding; Philippe Gevaert; Shuaib Nasser; Stephen R Durham; Marjolein E Cornet; Harsha H Kariyawasam; Jane Gilbert; Daren Austin; Aoife C Maxwell; Richard P Marshall; Wytske J Fokkens
Journal:  J Allergy Clin Immunol       Date:  2017-07-04       Impact factor: 10.793

10.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

View more
  4 in total

1.  Measurement of some serum cytokines in nasal polyp and evaluation of its correlation with disease severity.

Authors:  Mustafa Güllüev; Abitter Yücel; Mehmet Erkan Kahraman; Mehmet Akif Bor
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-15       Impact factor: 2.503

2.  Evidence for role of acid-sensing ion channel 1a in chronic rhinosinusitis with nasal polyps.

Authors:  Ru Tang; Guangyi Ba; Mingxian Li; Zhipeng Li; Haibo Ye; Hai Lin; Weitian Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-03       Impact factor: 2.503

Review 3.  A Potential Role of Group 2 Innate Lymphoid Cells in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps.

Authors:  Yan Li; Wei Wang; Sun Ying; Feng Lan; Luo Zhang
Journal:  Allergy Asthma Immunol Res       Date:  2021-05       Impact factor: 5.764

4.  Nasal Epithelial Cells Activated with Alternaria and House Dust Mite Induce Not Only Th2 but Also Th1 Immune Responses.

Authors:  Seung-Heon Shin; Mi-Kyung Ye; Dong-Won Lee; Mi-Hyun Chae; Ba-Da Han
Journal:  Int J Mol Sci       Date:  2020-04-13       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.